knowledge -WSS

knowledge

author：entertainment 2025-10-01 20:14:42 - browse：84395

ADAM FEUERSTEIN/STAT

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up here.

CHICAGO — It’s only Day 2, but the ASCO meeting is already in full force. That means hordes of oncologists filling the halls, reams of data streaming through the meeting, and incredibly long lines for even the worst food. And STAT reporters Angus Chen, Adam Feuerstein, and Matthew Herper are in the thick of it – on the heels of STAT’s own in-person event here, which was standing room only and came with its own share of thrills, chills, and not a little bit of audience laughter. More on that in a bit.

Here’s a rundown of some of the big news from the first 24 hours of the meeting which, due to some weird kind of relativistic time dilation, represents about a week for our intrepid reporters.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Sanofi says it has 12 blockbusters on the way. Will investors believe it?

WSS

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

AI can decode, harness the power of the humane immune system

Chemotherapy shortages won’t get better under Biden’s latest plan

Why sickle cell disease is getting the first CRISPR treatment

Roche to buy Carmot Therapeutics, developer of obesity drugs

Spinal cord stimulation reduces pain in amputees, study finds

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

3 questions for the future of Biden's cancer moonshot

State Dept. review finds Biden bears some blame for Afghanistan failures

Leukemia patients are helped by Syndax's new type of therapy

Wildfire smoke exposes gaps in outdoor worker protections

What causes an itch? Researchers may have solved the mystery

Hepatitis C has a cure — but many Americans still lack access to it

Chan Zuckerberg Biohub Chicago to focus on inflammation

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

SCOTUS to consider access to abortion pill mifepristone

focus

Roche to buy Carmot Therapeutics, developer of obesity drugs

Chemotherapy shortages won’t get better under Biden’s latest plan

Spinal cord stimulation reduces pain in amputees, study finds

SCOTUS to consider access to abortion pill mifepristone

The woman behind the Dana Farber

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

entertainment

leisure time

entertainment

hotspot